Pedro A. Piedra

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech, Gary Albert, Iksung Cho et al. · New England Journal of Medicine · 2020 · 1.2K citations · Full text

The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in Children

Robert B. Belshe, Paul M. Mendelman, John J. Treanor et al. · New England Journal of Medicine · 1998 · 918 citations · Full text

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Jing-Hui Tian, Nita Patel, Robert Haupt et al. · Nature Communications · 2021 · 517 citations · Full text

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

Robert B. Belshe, William C. Gruber, Paul M. Mendelman et al. · The Journal of Pediatrics · 2000 · 430 citations

Vaccination, Vaccine Safety, Cross-protection +7

Correlates of Immune Protection Induced by Live, Attenuated, Cold‐Adapted, Trivalent, Intranasal Influenza Virus Vaccine

Robert B. Belshe, William C. Gruber, Paul M. Mendelman et al. · The Journal of Infectious Diseases · 2000 · 412 citations